[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Altimmune Reports Tomorrow With Breakthrough Therapy Status but No Clear Path to Profitability

Altimmune Inc (ALT) reports first quarter 2026 earnings before market open on May 13, 2026, with analysts expecting continued losses as the late-stage biopharmaceutical company advances its lead candidate pemvidutide through clinical trials for metabolic and liver diseases. The central question is whether the company can demonstrate progress in its pipeline while managing cash burn, particularly as Wall Street maintains a bullish long-term outlook despite near-term technical weakness. With the stock trading at $3.08 and down nearly 50% over the past year, this report will test investor confidence in the company's path to commercialization.

Altimmune is a late-stage biopharmaceutical company developing pemvidutide, a dual-action therapy...

Fundamentals

See More
  • Market Capitalization, $K 400,723
  • Shares Outstanding, K 130,105
  • Annual Sales, $ 40 K
  • Annual Income, $ -88,090 K
  • EBIT $ -94 M
  • EBITDA $ -96 M
  • 60-Month Beta 0.18
  • Price/Sales 9,805.47
  • Price/Cash Flow N/A
  • Price/Book 1.55

Options Overview Details

View History
  • Implied Volatility 60.14% (-27.18%)
  • Historical Volatility 76.13%
  • IV Percentile 3%
  • IV Rank 3.26%
  • IV High 444.78% on 12/29/25
  • IV Low 47.16% on 08/20/25
  • Expected Move (DTE 1) 0.09 (2.81%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 5,014
  • Volume Avg (30-Day) 5,105
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 149,455
  • Open Int (30-Day) 131,384
  • Expected Range 2.94 to 3.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 5
  • High Estimate $-0.23
  • Low Estimate $-0.28
  • Prior Year $-0.26
  • Growth Rate Est. (year over year) +3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.56 +17.97%
on 05/01/26
3.64 -17.03%
on 04/21/26
-0.21 (-6.50%)
since 04/13/26
3-Month
2.56 +17.97%
on 05/01/26
4.83 -37.47%
on 02/24/26
-1.51 (-33.33%)
since 02/13/26
52-Week
2.56 +17.97%
on 05/01/26
7.73 -60.93%
on 06/25/25
-2.74 (-47.57%)
since 05/13/25

Most Recent Stories

More News
Altimmune Announces First Quarter 2026 Financial Results and Business Update

Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30...

ALT : 3.02 (-1.95%)
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL Oral presentation will highlight further the 48-week IMPACT efficacy...

ALT : 3.02 (-1.95%)
Altimmune Reports Tomorrow With Breakthrough Therapy Status but No Clear Path to Profitability

Barchart Research What to Expect from ALT Earnings ALT Generated May 12, 2026 Current Price $3.08 EPS Estimate $$-0.25 Consensus Rating Strong Buy Average Move 11.79% Altimmune Reports Tomorrow With Breakthrough...

ALT : 3.02 (-1.95%)
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced...

ALT : 3.02 (-1.95%)
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track...

ALT : 3.02 (-1.95%)
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today...

ALT : 3.02 (-1.95%)
Altimmune Announces Proposed Underwritten Public Offering of Securities

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today...

ALT : 3.02 (-1.95%)
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder...

ALT : 3.02 (-1.95%)
Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today...

ALT : 3.02 (-1.95%)
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced...

ALT : 3.02 (-1.95%)

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 3.23
2nd Resistance Point 3.13
1st Resistance Point 3.08
Last Price 3.02
1st Support Level 2.93
2nd Support Level 2.83
3rd Support Level 2.78

See More

52-Week High 7.73
Fibonacci 61.8% 5.76
Fibonacci 50% 5.14
Fibonacci 38.2% 4.53
Last Price 3.02
52-Week Low 2.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.